BiotechTube

Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Atherosclerosis

Conditions

Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia

Trial Timeline

Jun 1, 2026 → Oct 2, 2028

NCT ID
NCT07474649

About Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin is a phase 3 stage product being developed by Daiichi Sankyo for Coronary Atherosclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07474649. Target conditions include Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT07474649Phase 3Recruiting
NCT06686615Pre-clinicalRecruiting

Competing Products

20 competing products in Coronary Atherosclerosis

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
ExenatideEli LillyPhase 3
77
Clopidogrel treatment groupYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
77
statins, ezetimibe + Combination therapyYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
85
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
PrasugrelDaiichi SankyoApproved
85
ADP receptor inhibitorsDaiichi SankyoPre-clinical
23
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
52
prasugrel + clopidogrelDaiichi SankyoPhase 1
33
Prasugrel + ClopidogrelDaiichi SankyoApproved
85
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85